Aurobindo Pharma subsidiary launches generic of cancer drug

Aurobindo Pharma subsidiary Eugia Pharma Specialities has launched Pomalidomide Capsules, in different strengths, in the U.S. market.

Eugia was one of the first-to-file (FTF) ANDA applicants for the product and will manufacture the product, which is used to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma, at its Unit-I.

The product is a generic equivalent of BMS Pharmaceuticals Corp’s Pomalyst Capsules. In the U.S. for the twelve months ending January 2026, Pomalidomide capsules had an estimated market size of around $ 3.3 billion, Aurobindo Pharma said citing IQVIA MAT data.